Understanding lung endothelial barrier integrity in sepsis
Molecular Subtype-Specific Mechanisms and Therapeutic Strategies in Sepsis
This study is trying to find out how the lungs are affected in people with sepsis to see if certain blood markers can help predict their recovery and guide better treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 460 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mater Dei Hospital, Malta Academic / other |
| Locations | 1 site (Msida) |
| Trial ID | NCT06287684 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the dynamics of lung endothelial barrier integrity in patients with sepsis, septic shock, and pneumonia. It aims to classify sepsis patients into molecular endotypes to better understand their prognosis and response to treatment. By utilizing blood transcriptomics and bronchoalveolar lavage protein profiling, the study seeks to identify specific biomarkers associated with poor outcomes in sepsis. The findings could help tailor therapeutic interventions based on individual patient profiles.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with acute respiratory tract infections due to pneumonia.
Not a fit: Patients who are pregnant, prisoners, or have conditions like aspiration pneumonitis or ventilator-associated pneumonia may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment strategies for sepsis patients, improving their outcomes.
How similar studies have performed: While the approach of classifying sepsis patients into molecular endotypes is gaining traction, this specific study's methodology is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Age ≥ 18 years * Consent card signed Exclusion criteria: * Consent card not signed * Pregnancy * Prisoners * Elective cardiac surgery patients with an uncomplicated stay.
Where this trial is running
Msida
- Mater Dei hospital, Intensive Therapy Unit — Msida, Malta (Recruiting)
Study contacts
- Study coordinator: Brendon P. Scicluna, Ph.D.
- Email: brendon.scicluna@um.edu.mt
- Phone: +35623403869
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.